GlassScriptPhysician profile
Andrew Q Weeks
NPI 1346504768
$9,561.93
in general payments reported to CMS, 2019-2025
32 companies · $2,329 in 2025
The $2,329 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $245 · 2021: $143 · 2022: $939 · 2023: $2,530 · 2024: $2,169 · 2025: $2,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,939 · Education: $89.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,938.78 |
| Education | $89.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,690.67 | 2019-2024 | Exalt Model D |
| Abbvie INC. | $1,674.53 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,073.44 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $785.32 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $741.96 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $598.00 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $321.56 | 2022-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $304.36 | 2023-2025 | Dupixent |
| Pfizer INC. | $265.91 | 2019-2025 | |
| Madrigal Pharmaceuticals | $217.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $184.67 | 2022-2023 | Gi Genius |
| Gilead Sciences, INC. | $178.58 | 2022-2025 | |
| Celltrion USA INC. | $167.16 | 2024-2025 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $147.27 | 2023-2024 | Dificid |
| Genzyme Corporation | $145.56 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $143.53 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $141.50 | 2024-2025 | Voquezna |
| Apollo Endosurgery US INC | $125.67 | 2023 | Overstitch Endoscopic Suturing System |
| Ardelyx, INC. | $120.40 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $117.72 | 2022-2025 | Ocaliva |
| Fresenius Kabi USA, LLC | $56.09 | 2023-2024 | Idacio |
| Enterra Medical, INC. | $53.82 | 2023 | |
| Aimmune Therapeutics, INC. | $52.11 | 2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $40.73 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $38.77 | 2023 | Sutab, Suflave |
| Evoke Pharma, INC. | $35.79 | 2023-2024 | Gimoti |
| Alexion Pharmaceuticals, INC. | $31.86 | 2022-2023 | Ultomiris |
| Nestle Healthcare Nutrition INC. | $31.46 | 2022-2023 | |
| Erbe USA INC | $28.88 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.89 | 2023 | Terlivaz |
| Inspire Medical Systems, INC. | $14.78 | 2023 | Inspire |
| Conmed Corporation | $14.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.